AR016070A1 - Forma polimorfica cristalina 1 del compuesto sal acetato de metil-n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una protein - Google Patents

Forma polimorfica cristalina 1 del compuesto sal acetato de metil-n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una protein

Info

Publication number
AR016070A1
AR016070A1 ARP980102847A ARP980102847A AR016070A1 AR 016070 A1 AR016070 A1 AR 016070A1 AR P980102847 A ARP980102847 A AR P980102847A AR P980102847 A ARP980102847 A AR P980102847A AR 016070 A1 AR016070 A1 AR 016070A1
Authority
AR
Argentina
Prior art keywords
methyl
formamidinophenyl
diaminopropionate
roxifiban
isoxazolin
Prior art date
Application number
ARP980102847A
Other languages
English (en)
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of AR016070A1 publication Critical patent/AR016070A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forma polimorfica cristalina 2 del compuesto sal acetato de metil-N3-[2-{3,4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-N2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (Roxifiban) de la formula estructural (I), dicho polimorfo se distingue porel espectro RMN CP/MAS de 13C en estado solido de acuerdo con lafigura 1. Se describe asimismo la composicion farmacéutica que lo contiene asi como su uso en la preparacion de un medicamento util para tratar o prevenirtrastornos asociados a laadhesi on de proteínas solubles.
ARP980102847A 1997-06-16 1998-06-16 Forma polimorfica cristalina 1 del compuesto sal acetato de metil-n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una protein AR016070A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4963397P 1997-06-16 1997-06-16
US4971297P 1997-06-16 1997-06-16
US8027898P 1998-04-01 1998-04-01

Publications (1)

Publication Number Publication Date
AR016070A1 true AR016070A1 (es) 2001-06-20

Family

ID=27367578

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980102847A AR016070A1 (es) 1997-06-16 1998-06-16 Forma polimorfica cristalina 1 del compuesto sal acetato de metil-n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una protein
ARP000102123A AR023840A2 (es) 1997-06-16 2000-05-03 Forma polimerica cristalina 2 del compuesto acetato de metil -n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una proteina ad

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP000102123A AR023840A2 (es) 1997-06-16 2000-05-03 Forma polimerica cristalina 2 del compuesto acetato de metil -n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una proteina ad

Country Status (18)

Country Link
US (1) US6306886B1 (es)
EP (1) EP0991630A1 (es)
JP (1) JP2002504153A (es)
KR (1) KR20010013790A (es)
CN (1) CN1259940A (es)
AR (2) AR016070A1 (es)
AU (1) AU751198B2 (es)
CA (1) CA2294047A1 (es)
EA (1) EA200000028A1 (es)
EE (1) EE9900573A (es)
HR (1) HRP980291A2 (es)
HU (1) HUP0004755A3 (es)
IL (1) IL132618A0 (es)
NO (1) NO996182L (es)
NZ (1) NZ502077A (es)
PL (1) PL337612A1 (es)
SK (1) SK166699A3 (es)
WO (1) WO1998057939A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
US6908907B2 (en) * 2002-04-22 2005-06-21 El-Naggar Mawaheb M. Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
MY156670A (en) * 2010-05-27 2016-03-15 Du Pont Crystalline form of 4-[5-[3-chloro-5-(trifluoromethly)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl) amino]ethyl]-1-naphthalenecarboxamide
CN103534584B (zh) * 2011-05-17 2016-05-04 齐塔库比有限责任公司 使用同步辐射检测多晶型物的方法
GB2515783B (en) * 2013-07-03 2018-07-11 Rotam Agrochem Int Co Ltd Process for preparing clomazone, a form and use of the same
KR20240037628A (ko) 2022-09-15 2024-03-22 문혜경 그래핀이 함유된 고강도 내열 안경렌즈 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ES2154326T3 (es) * 1993-11-24 2001-04-01 Du Pont Pharm Co Antagonistas de receptor de fibrinogeno de isoxazolina e isoxazol.

Also Published As

Publication number Publication date
NZ502077A (en) 2002-03-01
CA2294047A1 (en) 1998-12-23
KR20010013790A (ko) 2001-02-26
NO996182D0 (no) 1999-12-14
AR023840A2 (es) 2002-09-04
HRP980291A2 (en) 1999-04-30
HUP0004755A2 (hu) 2001-07-30
HUP0004755A3 (en) 2002-10-28
EP0991630A1 (en) 2000-04-12
EE9900573A (et) 2000-08-15
CN1259940A (zh) 2000-07-12
JP2002504153A (ja) 2002-02-05
NO996182L (no) 1999-12-14
SK166699A3 (en) 2001-09-11
WO1998057939A1 (en) 1998-12-23
AU8071998A (en) 1999-01-04
AU751198B2 (en) 2002-08-08
PL337612A1 (en) 2000-08-28
US6306886B1 (en) 2001-10-23
EA200000028A1 (ru) 2000-08-28
IL132618A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
DK1326613T3 (da) Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering
BR9916590A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, método para a produção de um efeito anti-câncer em um animal de sangue quente, uso do derivado de pirimidina, e, composição farmacêutica
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
DE69922676D1 (de) N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
ES2013067A6 (es) Un procedimiento para producir un derivado de piperazina.
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
YU46095A (sh) Postupak pripreme leka za inhalacionu primenu
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
AR009741A1 (es) Nuevos derivados de la benzamidina, procedimiento para prepararlos, preparados farmaceuticos que los contienen y su empleo como medicamentos.
BR0316690A (pt) Composto, prodroga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR0016133A (pt) Composto, formulação farmacêutica, e, uso de um composto
BR0012610A (pt) Novo derivado de difenilpiperidina
DK1194415T3 (da) Nye piperazinylalkylthiopyrimidinderivater, farmaceutiske sammensætninger indeholdende disse samt en fremgangsmåde til deres fremstilling
AR016070A1 (es) Forma polimorfica cristalina 1 del compuesto sal acetato de metil-n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una protein
EP0902018A3 (en) 2-(Arylphenyl)amino-imidazoline derivatives
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
FR2767527B1 (fr) Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
KR910000647A (ko) 나프틸아미노-및 나프틸옥시- 피리딘아민 및 관련된 화합물, 이의 제조방법 및 이의 피부소염제로서의 용도
TR200202544T2 (tr) Torasemid'in yeni polimorfu V
WO2001017955A3 (en) Hydroxyacetamidobenzenesulphonamide derivatives
KR930019212A (ko) 피소스티그민 유도체와 이의 용도 및 이를 함유한 제약적 조제물

Legal Events

Date Code Title Description
FA Abandonment or withdrawal